BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB
C4221023
Phase 2 small_molecule active
Quick answer
BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB for Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma is a Phase 2 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active